Results 131 to 140 of about 3,028,209 (373)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib

JAMA Network Open, 2019
Key Points Question What is the potential upper bound of off-label use of erdafitinib in cancers with fibroblast growth factor receptor (FGFR) alterations?
Lélia Maria de Almeida Carvalho, Sandra de Oliveira Sapori Avelar, A. Haslam, J. Gill, V. Prasad   +4 more
semanticscholar   +1 more source

Structural insights into lacto‐N‐biose I recognition by a family 32 carbohydrate‐binding module from Bifidobacterium bifidum

FEBS Letters, EarlyView.
Bifidobacterium bifidum establishes symbiosis with infants by metabolizing lacto‐N‐biose I (LNB) from human milk oligosaccharides (HMOs). The extracellular multidomain enzyme LnbB drives this process, releasing LNB via its catalytic glycoside hydrolase family 20 (GH20) lacto‐N‐biosidase domain.
Xinzhe Zhang, Naoki Sunagawa, Toma Kashima, Kiyohiko Igarashi, Akimasa Miyanaga, Shinya Fushinobu   +5 more
wiley   +1 more source

Data_Sheet_1_Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients.docx

, 2021
Giulio Frontino (11833832), Tara Raouf (11833835), Daniele Canarutto (11833838), Eva Tirelli (11833841), Raffaella Di Tonno (11833844), Andrea Rigamonti (11600900), Maria Lucia Cascavilla (11833847), Cristina Baldoli (10662528), Roberta Scotti (11833850), Letizia Leocani (2839559), Su-Chun Huang (11833853), Franco Meschi (11833856), Graziano Barera (6579551), Vania Broccoli (54042), Greta Rossi (11833859), Silvia Torchio (611349), Raniero Chimienti (5792720), Riccardo Bonfanti (11510701), Lorenzo Piemonti (249842)   +18 more
openalex   +2 more sources

Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. [PDF]

, 2020
There is a great and growing need to ascertain what exactly is the state of a patient, in terms of disease progression, actual care practices, pathology, adverse events, and much more, beyond the paucity of data available in structured medical record ...
Butte, Atul J, Fan, Xuancheng, Glicksberg, Benjamin S, Goldstein, Theodore, Ludwig, Dana, Muenzen, Kathleen, Norgeot, Beau, Oskotsky, Boris, Peterson, Thomas A, Rutenberg, Eugenia, Schenk, Gundolf, Schmajuk, Gabriela, Sirota, Marina, Yazdany, Jinoos   +13 more
core   +1 more source

The Caenorhabditis elegans DPF‐3 and human DPP4 have tripeptidyl peptidase activity

FEBS Letters, EarlyView.
The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
wiley   +1 more source

5PSQ-053 Off-label use of rituximab in systemic autoimmune diseases [PDF]

, 2020
A Vilariño Seijas, A Morales Triadó, Lydia Carabias Ané, G Cardona Peitx, E Valls Sánchez, C Codina Jiménez, C Quiñones Ribas   +6 more
openalex   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Molecular bases of circadian magnesium rhythms across eukaryotes

FEBS Letters, EarlyView.
Circadian rhythms in intracellular [Mg2+] exist across eukaryotic kingdoms. Central roles for Mg2+ in metabolism suggest that Mg2+ rhythms could regulate daily cellular energy and metabolism. In this Perspective paper, we propose that ancestral prokaryotic transport proteins could be responsible for mediating Mg2+ rhythms and posit a feedback model ...
Helen K. Feord, Gerben van Ooijen
wiley   +1 more source

Off-label use of upadacitinib in dermatology: a review

Journal of Dermatological Treatment
Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Hongtao Yu, Junkai Zhu, Xiaoli Ni, Kaiyu Yu, Zhen Mu   +4 more
doaj   +1 more source

Drug utilisation and off-label use of medications in anaesthesia in surgical wards of a teaching hospital

Indian Journal of Anaesthesia, 2015
Background and Aims: When a drug is used in a way that is different from that described in regulatory body approved drug label, it is said to be ′off label use′. Perioperative phase is sensitive from the point of view of patient safety and off-label drug
Amol E Patil, Yashashri C Shetty, Snehalata V Gajbhiye, Sweta V Salgaonkar   +3 more
doaj   +1 more source